To gain further insight into the molecular mechanism of the inhibitory effects of YLT192 on tumor cells we evaluated the expression of p44/42 MAPK, STAT3, AKT, and mammalian target of rapamycin (mTOR) in U251 and HCT116 cells 48 h after treatment. The gene discussed is AKT1; the disease is neoplasm.